Fundraising Fox
Oculogica
New York, US · Founded 2013 · Delaware corporation · 14 employees on LinkedIn · 7 known investors
Find your way into Oculogica
Sign up to see every warm intro you have to Oculogica
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oculogica team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Oculogica develops FDA-cleared concussion assessment devices that use proprietary eye-tracking technology to measure abnormal eye movements caused by traumatic brain injury. Its tools serve clinicians and athletic trainers across settings including sports sidelines, pediatric and urgent care clinics, accident/personal injury clinics, and military care.
Founders & leadership
Oculogica was founded in 2013 by Rosina Samadani and Uzma Samadani.
Board
Investors · 7
How we know: Colle Capital Partners's portfolio page · Not right? Tell us
How we know: Southeast Minnesota Capital Fund's portfolio page · Not right? Tell us
How we know: StartX's portfolio page · Not right? Tell us
How we know: TitletownTech's portfolio page · board seat on SEC Form D · funding news · oculogica.com · the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$22M disclosed across 5 rounds · 2014–2024
▶$7.6MraisedMay 2024 · 24 investors · BiotechnologyRule 506(b)
- Jim FlanniganDirector
- Kathryn SwintekDirector
- Rosina SamadaniExecutive Officer, Director
- Pratipatti LaxminarainDirector
- Jill EnosDirector
- Uzma SamadaniDirector
- Offering amount
- $18M
- Amount sold
- $7.6M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedJun 2022 · 20 investors · Other Health CareRule 506(b)
- Jill EnosDirector
- Kathryn SwintekDirector
- Uzma SamadaniDirector
- Pratipatti LaxminarainDirector
- Rosina SamadaniExecutive Officer, Director
- Offering amount
- $4.5M
- Amount sold
- $4M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.1MraisedJan 2020 · 41 investors · Other Health CareRule 506(b)
- Jill EnosDirector
- Rosina SamadaniExecutive Officer, Director
- Uzma SamadaniDirector
- Kathryn SwintekDirector
- Pratipatti LaxminarainDirector
- Offering amount
- $8.6M
- Amount sold
- $8.1M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.7MraisedMar 2016 · 8 investors · BiotechnologyRule 506(b)
- Rosina SamadaniExecutive Officer
- Bilal KhanDirector
- Uzma SamadaniDirector
- Jason HuangDirector
- Offering amount
- $2.5M
- Amount sold
- $1.7M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$600KraisedJul 2014 · 6 investors · BiotechnologyRule 506(b)
- Jason HuangDirector
- Uzma SamadaniDirector
- Robert RitlopExecutive Officer
- Bilal KhanDirector
- Offering amount
- $1000K
- Amount sold
- $600K
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Oculogica.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $553.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Oculogica do?
- Oculogica develops FDA-cleared concussion assessment devices that use proprietary eye-tracking technology to measure abnormal eye movements caused by traumatic brain injury. Its tools serve clinicians and athletic trainers across settings including sports sidelines, pediatric and urgent care clinics, accident/personal injury clinics, and military care.
- Who founded Oculogica?
- Oculogica was founded by Rosina Samadani, Uzma Samadani in 2013.
- Who are Oculogica's investors?
- Oculogica's investors include Colle Capital Partners, Seraph Group, Southeast Minnesota Capital Fund, StartX, TitletownTech, Golden Seeds, M12 (Microsoft's Venture Fund).
- How much funding has Oculogica raised?
- Oculogica has disclosed $22M raised across 5 rounds.
- Where is Oculogica headquartered?
- Oculogica is headquartered in New York, US.